-
1.发明公开DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA 有权屈昔多巴和药物组合物及其用于治疗纤维肌痛
公开(公告)号：EP2134335A1
公开(公告)日：2009-12-23
申请号：EP08731699.8
申请日：2008-03-07
IPC分类号： A61K31/195 , A61K31/198 , A61K31/277 , A61K31/435 , A61P25/16 , A61P25/00
CPC分类号： A61K31/195 , A61K31/198 , A61K31/277 , A61K31/435 , A61K2300/00
摘要： The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.
-
2.发明公开QUINAZOLINE DERIVATIVES AS METABOLICALLY INERT ANTIFOLATE COMPOUNDS 审中-公开CHINAZOLINDERIVATE ALS代谢物INTETE抗体
公开(公告)号：EP1791544A2
公开(公告)日：2007-06-06
申请号：EP05806392.6
申请日：2005-09-08
IPC分类号： A61K31/505 , C07D239/95
CPC分类号： C07D239/95
摘要： The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.
-
3.发明公开DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION 有权屈昔多巴及其药物组合物的神经介导治疗高血压病
公开(公告)号：EP2142185A2
公开(公告)日：2010-01-13
申请号：EP08732012.3
申请日：2008-03-12
IPC分类号： A61K31/15 , A61K31/198 , A61K31/275 , A61K31/407 , A61P9/02
CPC分类号： A61K45/06 , A61K31/15 , A61K31/198 , A61K31/275 , A61K31/277 , A61K31/407 , A61K31/4409 , A61K31/4425 , A61K2300/00
摘要： The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension.
-
公开(公告)号：EP1948155A2
公开(公告)日：2008-07-30
申请号：EP07784556.8
申请日：2007-06-28
IPC分类号： A61K31/198 , A61P9/02 , A61K31/275 , A61K31/27 , A61K31/15
CPC分类号： A61K31/198 , A61K31/12 , A61K31/15 , A61K31/27 , A61K31/275 , A61K31/277 , A61K31/44 , A61K31/4409
摘要： The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations.
-
5.发明授权DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA 有权屈昔多巴和药物组合物及其用于治疗纤维肌痛
公开(公告)号：EP2134335B1
公开(公告)日：2014-04-23
申请号：EP08731699.8
申请日：2008-03-07
IPC分类号： A61K31/195 , A61K31/198 , A61K31/277 , A61K31/435 , A61P25/16 , A61P25/00
CPC分类号： A61K31/195 , A61K31/198 , A61K31/277 , A61K31/435 , A61K2300/00
-
公开(公告)号：EP1948155B1
公开(公告)日：2012-03-07
申请号：EP07784556.8
申请日：2007-06-28
IPC分类号： A61K31/198 , A61P9/02 , A61K31/275 , A61K31/27 , A61K31/15
CPC分类号： A61K31/198 , A61K31/12 , A61K31/15 , A61K31/27 , A61K31/275 , A61K31/277 , A61K31/44 , A61K31/4409
摘要： The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations.
-
7.发明授权DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF ATTENTION DEFICIT DISORDERS 有权屈昔多巴及其药物组合物注意力缺陷障碍的治疗
公开(公告)号：EP2167066B1
公开(公告)日：2013-06-26
申请号：EP08769311.5
申请日：2008-05-07
IPC分类号： A61K31/198 , A61K31/195 , A61K31/275 , A61K31/138 , A61K31/345 , A61K45/06
CPC分类号： A61K31/198 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/195 , A61K31/275 , A61K31/277 , A61K31/345 , A61K31/55 , A61K45/06 , A61K2300/00
-
8.发明授权DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION 有权屈昔多巴及其药物组合物的神经介导治疗高血压病
公开(公告)号：EP2142185B1
公开(公告)日：2012-08-15
申请号：EP08732012.3
申请日：2008-03-12
IPC分类号： A61K31/15 , A61K31/198 , A61K31/275 , A61K31/407 , A61P9/02
CPC分类号： A61K45/06 , A61K31/15 , A61K31/198 , A61K31/275 , A61K31/277 , A61K31/407 , A61K31/4409 , A61K31/4425 , A61K2300/00
摘要： The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension.
-
9.发明公开
公开(公告)号：EP2167066A2
公开(公告)日：2010-03-31
申请号：EP08769311.5
申请日：2008-05-07
IPC分类号： A61K31/138 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/345
CPC分类号： A61K31/198 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/195 , A61K31/275 , A61K31/277 , A61K31/345 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-0-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).
-
公开(公告)号：EP2125818A1
公开(公告)日：2009-12-02
申请号：EP08727890.9
申请日：2008-01-18
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention is directed to antifolate compounds having the structure of formula (I). wherein: X is CHR9 or NR9; Y1, Y2, and Y3 independently are O or S; V1 and V2 independently are O, S, or NZ; Z is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl; R1 and R2 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or alkaryl; R3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, hydroxyl, or halo; and R4, R5, R6, R7, Rs, and R9 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, -C(O)-alkyl, - C(O)-alkenyl, or -C(O)-alkynyl; as well as pharmaceutically acceptable esters, amides, salts, solvates, and prodrugs thereof. The compounds are useful in pharmaceutical compositions and in methods of treating multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.017 秒)
